# Robert J. Motzer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-j-motzer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 125,211 |
| Field | Renal cell carcinoma treatment |
| h-index | 150 |
| i10-index | 701 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5059063118 |
| ORCID iD | https://orcid.org/0000-0001-6925-2327 |
| Works | 1,584 |

## Researcher papers

Showing 12 of 19.

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/temsirolimus-interferon-alfa-or-both-for-advanced-renal-cell-carcinoma/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/pazopanib-versus-sunitinib-in-metastatic-renal-cell-carcinoma/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients](https://scholariq.org/papers/genomic-characterization-of-metastatic-patterns-from-prospective-clinical/)
- [Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing](https://scholariq.org/papers/mutation-detection-in-patients-with-advanced-cancer-by-universal-sequencing-of/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Testicular diseases and treatments](https://scholariq.org/topics/testicular-diseases-and-treatments-2/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.